Pharmacoepigenetics, Second Edition, a volume within the Translational Epigenetics series, is a comprehensive reference on the role of epigenetics and epigenomics in drug discovery and development, providing a detailed, but accessible view of the field, from basic principles to applications in disease therapeutics. Leading international researchers from across academia, clinical settings, and the pharmaceutical industry discuss the influence of epigenetics and epigenomics in human pathology, epigenetic biomarkers for disease prediction, diagnosis, and treatment, current epigenetic drugs, and the application of epigenetic procedures in drug development. Throughout the book, chapter authors offer a balanced and objective discussion of the future of pharmacoepigenetics and its crucial contribution to the growth of precision and personalized medicine.The new edition has been fully revised to address recent advances in epigenetics, from new natural and synthetic compounds with epigenetic effects to the role of epigenetics in the pathogenesis of a growing number of complex diseases, including further cancers, cardiovascular disorders, and brain disorders. Newly identified molecular components in the functional architecture of the epigenetic machinery, as well as practical and relevant pharmacoepigenetics topics related to COVID-19 and other world health challenges, are also discussed. Each chapter has been updated to include a chapter summary, keywords and definitions, and further color figure and charts for learning reinforcement, along with clinical research case studies illustrating key research in the field and making findings and research approaches more actionable for readers. - Fully examines the influence of epigenetics and epigenomics in human pathology, epigenetic biomarkers for disease prediction, diagnosis, treatment, current epigenetic drugs, and the application of epigenetic procedures in drug development - Features chapter contributions from leading international researchers in academia, clinical settings, and the pharmaceutical industry - Instructs researchers, students, and clinicians in better interpreting and employing pharmacoepigenetics in drug development, efficiency, and safety - Incorporates recent advances, including epigenetic drugs and biomolecules with epigenetic effects in cancer, cardiovascular disorders, brain disorders, and COVID-19 - Includes chapter definitions, key words, and summaries to reinforce understanding, as well clinical research case studies illustrating key research in the field
